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Abstract
This naturalistic study among patients with alcohol dependence examined whether routine blood biomarkers could help to 
identify patients with high risk for relapse after withdrawal treatment. In a longitudinal study with 6-month follow-up among 
133 patients with alcohol dependence who received inpatient alcohol withdrawal treatment, we investigated the usefulness of 
routine blood biomarkers and clinical and sociodemographic factors for potential outcome prediction and risk stratification. 
Baseline routine blood biomarkers (gamma-glutamyl transferase [GGT], alanine aminotransferase [ALT/GPT], aspartate 
aminotransferase [AST/GOT], mean cell volume of erythrocytes [MCV]), and clinical and sociodemographic characteristics 
were recorded at admission. Standardized 6 months’ follow-up assessed outcome variables continuous abstinence, days of 
continuous abstinence, daily alcohol consumption and current abstinence. The combined threshold criterion of an AST:ALT 
ratio > 1.00 and MCV > 90.0 fl helped to identify high-risk patients. They had lower abstinence rates (P = 0.001), higher 
rates of daily alcohol consumption (P < 0.001) and shorter periods of continuous abstinence (P = 0.027) compared with low-
risk patients who did not meet the threshold criterion. Regression analysis confirmed our hypothesis that the combination 
criterion is an individual baseline variable that significantly predicted parts of the respective outcome variances. Routinely 
assessed indirect alcohol biomarkers help to identify patients with high risk for relapse after alcohol withdrawal treatment. 
Clinical decision algorithms to identify patients with high risk for relapse after alcohol withdrawal treatment could include 
classical blood biomarkers in addition to clinical and sociodemographic items.
Keywords Alcohol dependence · Alcohol use disorder · Withdrawal treatment · Risk for relapse · Outcome · Blood 
biomarkers
Introduction
Alcohol use disorder (AUD) is a severe, chronic substance 
use disorder with a significant individual and socio-eco-
nomic burden; it is highly prevalent and affects approx. 100 
million people globally [12]. Furthermore, about 40–60% 
of patients with AUD are presumed to relapse within the 
first year after treatment [11, 27]. Due to limited resources 
of health care systems, the effective allocation of medical 
treatment to individual patients is a major challenge [36]. 
A promising strategy to improve the outcome might be to 
individualize treatment and to identify patients on the basis 
of applicable subgroups and endophenotypes [24].
Biological and non-biological variables (e.g. sociode-
mographic, environmental and clinical factors) have been 
previously associated with the risk of relapse in patients 
or subgroups of patients with AUD [1, 8, 13, 29, 32, 38]. 
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Despite neuroimaging [8, 13], genetics [29] and the meas-
urement of neurometabolites [29] being sophisticated 
methods to estimate resilience and the risk of relapse after 
treatment, routine blood biomarkers might be a more fea-
sible and cost-effective means of assessing relapse risk. 
The classical indirect alcohol blood biomarkers are the 
liver enzymes γ-glutamyl transferase (GGT), alanine ami-
notransferase (ALT), aspartate aminotransferase (AST) 
and the mean cell volume of erythrocytes (MCV). All 
of them reflect chronic excessive drinking and are basic 
parameters for clinical laboratories in daily routine care 
settings [3, 25]. A previous study investigated the abil-
ity of a combination of an AST:ALT ratio > 1.00 and an 
MCV > 90.0 fl to identify patients with alcohol depend-
ence (AD) in a cohort of individuals with and without 
physical diseases and with and without elevated transami-
nase levels [17]. The combination of these routine blood 
biomarkers resulted in a remarkably high sensitivity of 
97.3% and specificity of 88.9% [17].
So far, most studies have investigated the use of blood 
biomarkers (1) to identify patients with AD and/or (2) as 
a screening tool for potential alcohol consumption before 
sample collection and/or (3) to detect relapse and monitor 
abstinence in patients with AD [2, 3, 20, 42].
Blood biomarkers might not only help to identify patients 
with AD or help to monitor therapeutic strategies and absti-
nence but might also serve as prognostic markers to assess 
the risk of relapse and thus might support future clinical 
decision algorithms [31]. Indirect alcohol biomarkers rep-
resent an objective measurement for chronic cellular impair-
ment that correlates with previous alcohol consumption [35] 
and, therefore, might reflect the severity of AD and conse-
quently the risk of relapse after withdrawal treatment. In 
this context, in a sample of individuals with alcohol abuse 
and dependence, higher levels of the blood biomarker CDT 
and the liver function enzymes ALT and GGT were predic-
tors for drunk-driving recidivism [23]. Furthermore, higher 
GGT scores were associated with unfavourable outcomes 
during and after pharmacotherapy for AD [15, 16]. In a 
longitudinal study assessing post-treatment outcomes in an 
outpatient sample with one-year follow-up after treatment, 
higher GGT, AST, ALT, MCV scores and AST/ALT ratios 
were associated with unfavourable outcomes with regard to 
drinking-behaviour [14].
In this study, we investigated the potential of biological 
(i.e. routine blood biomarkers, breath alcohol and alco-
holic liver disease) and non-biological factors (i.e. sociode-
mographic and clinical variables) to estimate the risk for 
relapse after inpatient withdrawal treatment. Therefore, we 
conducted a naturalistic longitudinal study among patients 
with AD in a routine care setting with a 6-month follow-
up to evaluate whether baseline both biological and non-
biological factors, assessed at admission to inpatient alcohol 
withdrawal treatment, are associated with long-term out-
come after completion of treatment.
Methods
Design
Included patients received routine inpatient care with a 
standardized multimodal and multi-professional qualified 
(extended) withdrawal treatment (QWT) at the inpatient 
addiction unit at the Department of Psychiatry and Psycho-
therapy, University Hospital, LMU Munich, Munich, Ger-
many. Information on biological and non-biological baseline 
variables at admission was obtained from standardized elec-
tronic medical records. Previous inpatients were contacted 
and interviewed 6 months after completion of treatment to 
assess relevant outcome variables. We chose 6 months as the 
follow-up period since this is presumed to be a good predic-
tor for 5-year outcome [40]. The study was approved by the 
local ethics committee of the Faculty of Medicine, LMU 
Munich, Germany (project number 585-16).
Participants
The study was conducted between September 2016 and 
January 2018. Inclusion criteria were: (1) patients with a 
confirmed diagnosis of AD (F10.2) according to the Interna-
tional Classification of Diseases and Related Health Prob-
lems 10th Revision (ICD-10), (2) treated at the inpatient 
addiction unit between March 18, 2016 and July 26, 2017, 
(3) age ≥ 18 years and (4) participation in QWT for ≥ 5 days.
On the basis of electronic records, we identified 338 
patients (71.3% male, 28.7% female, mean [SD] age: 46.7 
[12.6] years) with a recorded diagnosis of AD according to 
ICD-10 who had received ≥ 5 days of QWT in the period of 
interest. To exclude patients with a diagnosis other than AD 
(e.g. multiple drug abuse [F19.2]), trained physicians re-
assessed each patient’s diagnosis and excluded 24 patients 
with a diagnosis other than AD (e.g. multiple drug abuse 
[F19.2]). Thus, we contacted 314 former inpatients. 51.2% 
(161 out of 314) of previous inpatients could not be reached 
and 1 person (0.3%) declined to participate in the follow-
up interview. Of the successfully contacted people, 19 were 
excluded due to a protocol violation (they were contacted 
earlier than 6 months after QWT). Thus, a total of 133 out of 
314 (42.4%) former inpatients (71.4% males, 28.6% females, 
mean [SD] age 47.4 [13.0] years) were contacted success-
fully 6 months after QWT and interviewed by telephone. 
Figure 1 shows a detailed overview of the selection process.
Only two baseline features significantly differed between 
the study participants who were successfully contacted after 
6 months and those who were not reached by telephone 
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or were excluded (non-follow-up sample). More former 
inpatients in the non-follow-up group had an immigra-
tion background than in the participant group (43.1% vs. 
26.1%, χ2 = 4.263, df = 1, P = 0.039) and the prevalence of 
alcoholic liver disease detected by ultrasound was higher in 
the non-follow-up group compared to the participant group 
(63.1% vs. 49.2%, χ2 = 5.682, df = 1, P = 0.017). All other 
baseline features including liver enzymes (AST, ALT, GGT) 
and MCV did not significantly differ between the follow-up 
group and the non-follow-up group.
Setting
QWT is a multimodal and multi-professional inpatient 
detoxification and treatment programme [5]. It is usually 
planned for 14–21 days and is a highly standardized part 
of routine clinical care in the inpatient addiction unit at 
the Department of Psychiatry and Psychotherapy, Univer-
sity Hospital, LMU Munich, Munich, Germany. Medical 
treatment to control acute alcohol withdrawal symptoms 
included the application of benzodiazepines (oxazepam) and 
alpha-2 noradrenergic agonists (clonidine). Patients received 
medication as needed, according to their clinical condition. 
Patients with a history of at least one epileptic seizure were 
additionally treated with a fixed dose of anticonvulsants 
(carbamazepine or levetiracetam). Patients also received 
their previously prescribed medication for their physical 
and psychiatric conditions. In addition to symptom-specific 
or prophylactic treatment of withdrawal symptoms, QWT 
includes psychotherapeutic interventions covering moti-
vational enhancement, cognitive behavioural therapy and 
relapse prevention; occupational therapy; physiotherapy; 
work-related therapy, art and music therapy; and attendance 
at self-help groups (e.g. AA groups). Abstinence during 
QWT was monitored with breath analysers for alcohol.
Baseline data
Baseline data at admission to inpatient treatment were 
extracted from standardized electronic medical records. 
At admission, all patients were interviewed with a stand-
ard questionnaire based on the European Addiction Sever-
ity Index (EuropASI) [19], a semi-structured assessment 
instrument for drug and alcohol abuse. The clinical 
records of study participants during QWT were used to 
assess baseline data of the patients. We collected baseline 
data on both biological (routine blood biomarkers [GGT, 
AST, ALT, MCV], breath alcohol and alcoholic liver dis-
ease detected by ultrasound) and non-biological factors 
(sociodemographic and clinical variables; see Table 1 
for details). We used the combined threshold criterion of 
Fig. 1  Overview of the selec-
tion process for the longitudinal 
study with 6-month follow-up 
among 133 patients with alco-
hol dependence who received 
inpatient alcohol withdrawal 
treatment
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an AST:ALT > 1.00 and a MCV > 90.0 fl [17] to divide 
participants into “low-risk patients”, who did not fulfil 
the criterion, and “high-risk patients”, who did. Baseline 
blood samples were collected within 72 h after admission 
and an ultrasound scan was performed to detect alcoholic 
liver diseases. Whole blood anticoagulated with EDTA 
was used to assess MCV with an automated haematology 
analyser and serum was used to determine y-GT, ALT and 
AST activity. All blood measurements were conducted at 
the Institute of Laboratory Medicine, University Hospital 
Munich.
Six‑month follow‑up measurements
Higher levels of individual self-reported motivation and self-
efficacy are presumed to be associated with better treatment 
outcomes in patients with AD [10, 22, 28]. Moreover, study 
designs with a written informed consent process for study 
participation might be prone to selection bias since popu-
lations are not comparable with real-world settings [18]. 
Our approach to modify the classical procedure of written 
informed consent in a three-step procedure was approved a 
priori by the local ethics committee: (1) 5.5 months after the 
end of QWT we used the addresses available in the hospital 
database to inform all former inpatients who had received 
QWT for AD in written form about the study. (2) Trained 
interviewers then attempted to contact all former inpatients 
by telephone 6 months (+ maximum 10 days) after the 
end of their QWT. The protocol specified that 10 attempts 
to reach a patient could be made at different time points 
during the day, including weekends. Finally, (3) Success-
fully contacted patients were asked whether they agreed to 
participate in the study that they had been informed about 
(i.e. we obtained oral informed consent). Then, the trained 
interviewers immediately conducted the semi-structured 
self-report follow-up interview to assess all outcome vari-
ables, as follows: (1) continuous abstinence from the end of 
QWT until follow-up (i.e. no alcohol use [no single drink]; 
yes/no), (2) duration (in days) of continuous abstinence 
(i.e. reported achieved days of continuous abstinence with 
no single drink after the end of QWT; if patients reported 
continuous abstinence for the full 6 months, the duration of 
continuous abstinence was recorded as 180 days), (3) daily 
alcohol consumption based on 30-day TLFB [37]; mean 
daily alcohol consumption was calculated in grams: etha-
nol [g] = volume of beverages × 0.8 g/l × alcohol content [in 
%]/100%) and current abstinence (no alcohol consumption 
in 30-day TLFB). Finally, the interviewers assessed partici-
pant satisfaction with the inpatient QWT programme using 
the Munich Patient Satisfaction Scale (MPSS-24) [26] and 
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Statistical analysis
Statistical analysis was performed with IBM SPSS25.0 soft-
ware (IBM, Armonk, NY, USA) with a significance level of 
α = 0.05. The Shapiro–Wilk test was used to assess whether 
data were normally distributed. Data were not transformed and 
we used both parametric (Student’s t-test, Pearson’s r) and non-
parametric analyses (Mann–Whitney U test, Kruskal–Wallis 
test, χ2 test, Fisher’s exact test, Spearman’s ρ), depending on 
the specific distribution properties. Correction for multiple 
testing using the family-wise error rate (FWE) was performed 
for families of tests within the same category (e.g. education, 
living situation). However, due to the exploratory nature of 
our analysis and our pre-defined aim of identifying candidate 
variables, no overall P-value correction was applied. Finally, 
baseline variables were used to predict both binary and con-
tinuous outcome features using logistic and linear regression 
analysis, respectively. Since our analyses on the relationship of 
biomarkers on relapse rates have to be considered exploratory 
rather than confirmatory, power analyses were not conducted.
Results
Participant characteristics
Of the 133 former inpatients included in the follow-up 
assessment (71.4% men, 28.6% women; mean [SD] age: 
47.4 [13.0] years), n = 59 participants (44.4%) reported 
being continuously abstinent since the end of their QWT. 
The mean (SD) duration of continuous abstinence was 
111.44 (72.17) days. A total of n = 103 participants (77.4%) 
reported current abstinence. The mean (SD) daily alcohol 
consumption among all participants, calculated on the basis 
of TLFB, was 20.47 (57.40) g. The mean [SD] satisfaction 
score on the MPSS-24 was 22.40 [4.0] (n = 132 for satisfac-
tion score; maximum score = 25). The satisfaction score did 
not differ between participants who were currently abstinent 
and those who were currently drinking according to TLFB 
(22.28 [4.04] vs. 22.83 [3.86]; U = 2139.5; P = 0.945), nor 
did it differ between continuously abstinent participants 
and those who had relapsed (22.51 [3.82] vs. 22.32 [4.16]; 
U = 2139.5; P = 0.945). Moreover, there was no significant 
correlation between the satisfaction score and daily alcohol 
consumption (ρ = 0.127; P = 0.148) or days of continuous 
abstinence (ρ = 0.026; P = 0.766). Table 1 presents all base-
line subject characteristics and outcome results.
Baseline sociodemographic and clinical variables 
associated with outcome variables
Several sociodemographic and clinical variables differed 
significantly between abstinent and relapsed participants or 
correlated significantly with days of continuous abstinence 
or current daily alcohol consumption (Table 1). With regard 
to sociodemographic variables, a higher educational level 
was associated with both a higher probability for current 
abstinence (P = 0.010) and a lower alcohol consumption 
(P = 0.011). Furthermore, employment status was associ-
ated with longer continuous abstinence (P = 0.036). With 
regard to clinical variables, participants with current absti-
nence had received less oxazepam as withdrawal medica-
tion (P = 0.041). Higher oxazepam use during withdrawal 
treatment significantly correlated with higher daily alcohol 
consumption at the 6-month follow-up (P = 0.028). A higher 
number of previous detoxifications and alcohol treatments 
correlated with a lower number of days of continuous absti-
nence (P = 0.009). Moreover, the breath alcohol level at 
admission was lower in participants with current abstinence 
at the 6-month follow-up (P = 0.046). Higher breath alco-
hol levels at admission correlated with higher mean daily 
alcohol consumption at the 6-month follow-up (P = 0.022).
Baseline blood biomarkers associated with outcome 
variables
No single blood biomarker at admission significantly dif-
fered between abstinent and relapsed participants or cor-
related with any outcome variable. We did observe a sig-
nificant correlation between the AST:ALT ratio and daily 
alcohol consumption at the 6-month follow-up (r = 0.232; 
P = 0.007). A total of n = 59 (44.4%) participants were 
high-risk patients, i.e. they fulfilled the above-mentioned 
risk threshold of an AST:ALT > 1.00 and MCV > 90.0 fl 
[17]. At the 6-month follow-up, n = 65/74 (87.8%) of the 
low-risk patients were currently abstinent compared with 
only n = 38/59 (64.4%) of the high-risk patients (P = 0.001). 
Moreover, mean (SD) daily alcohol consumption was sig-
nificantly higher among high-risk (42.25 [80.44] g) than in 
low-risk patients (3.10 [11.29], p < 0.001). Finally, high-risk 
patients achieved a shorter period of continuous abstinence 
(92.81 [71.26] days) than low-risk patients (126.28 [69.86] 
days, P = 0.027) (Table 1).
Ranking of baseline variables associated 
with outcome variables
For each baseline variable, we determined whether it was 
significantly associated with each of the four outcome varia-
bles, i.e. continuous abstinence, duration (in days) of contin-
uous abstinence, daily alcohol consumption based on TLFB 
and current abstinence. Table 2 highlights the ranking of the 
number of significant associations between the various base-
line factors and the four outcome variables. The combination 
criterion of AST:ALT > 1.00 and MCV > 90.0 fl at baseline 
was significantly associated with 3 of the 4 outcome varia-
bles; the baseline variables educational level, alcohol breath 
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concentration and amount of used withdrawal medication 
were each significantly associated with 2 of the 4 outcome 
variables; and the AST:ALT ratio, number of previous inpa-
tient treatments and employment status were significantly 
associated with 1 of the 4 outcome variables.
Regression analysis
To investigate effect sizes and to adjust for intervariable 
confounding effects, we performed regression analysis with 
those variables that were significantly associated with the 
respective outcome variable from Table 1. We performed 
logistic regression to investigate the relationship between 
the identified baseline variables and current abstinence. 
Individuals who did not fulfill the combination criterion of 
AST:ALT > 1.00 and MCV > 90.0 fl at baseline had a 3.52 
higher odds ratio to achieve abstinence 6 months after treat-
ment than patients who fulfilled the criterion. Besides the 
combination criterion, also higher education provided sig-
nificant higher odds ratios compared to basic school edu-
cation (Table 3). By performing linear regression analysis 
for the continuous outcome variables, the fulfilled combina-
tion criterion significantly explained parts of the outcome 
variances of daily alcohol consumption (effect size = 0.347) 
and days of continuous abstinence (effect size = − 0.190). 
Besides that, only breath alcohol level at admission signifi-
cantly predicted daily alcohol consumption 6 months later 
and number of previous inpatient treatments significantly 
explained parts of the variance of the achieved days of con-
tinuous abstinence (Table 4). 
Discussion
The aim of our naturalistic longitudinal study in people who 
had received extended alcohol withdrawal treatment was to 
analyse the potential of individual and combined routine 
blood biomarkers and clinical and sociodemographic vari-
ables to predict outcome 6 months later. 48.8% of inpatients 
were successfully contacted and interviewed 6 months after 
withdrawal treatment, whereas 51.2% could not be reached. 
A significant difference between the two groups could only 
be detected for two baseline parameters (migration status 
and liver disease detected by ultrasound). All other baseline 
features including blood biomarkers did not significantly 
differ between the follow-up group and the non-follow-up 
group. Hence, by receiving informed consent not during 
withdrawal treatment but 6 months later during the follow-
up survey, we were able to reduce potential selection bias 
compared to standard a priori written informed consent pro-
cedures [18]. Of note, a previous study in an outpatient set-
ting also assessed AST, ALT, GGT and MCV with a 1-year 
follow-up period in a longitudinal naturalistic approach in 
patients with AD. This study used written informed consent 
before study participation and reported a subsequent dropout 
rate of 44% [14].
Table 2  Ranking of baseline variables dependent on the number of significant associations with outcome variables
Significant P values (P < 0.05) are written in bold. Non-significant P values < 0.1 are specified, but P values > 0.1 are indicated as “–”.
AST aspartate aminotransferase, ALT alanine aminotransferase, MCV mean cell volume of erythrocytes
*Current abstinence: no alcohol consumption reported in 30-day timeline follow-back; continuous abstinence: no alcohol consumption since the 
end of inpatient withdrawal treatment
**Baseline variables with no significant associations and a P value ≤ 0.1 are included in the table, but baseline variables with no significant 
associations and a P value >0 .1 are not
Baseline factor No. of associations between base-
line factor and outcome variable
Outcome variable







AST:ALT > 1.00 + MCV > 90.0 fl 3 P = 0.001 P = 0.069 P < 0.001 P = 0.027
Education level 2 P = 0.010 – P = 0.011 –
Breath alcohol level P = 0.046 P = 0.088 P = 0.022 P = 0.068
Dose of oxazepam needed P = 0.041 – P = 0.028 –
AST:ALT ratio 1 P = 0.087 – P =0 .007 –
Previous inpatient treatment – P = 0.058 – P = 0.009
Employment status – P = 0.091 – P = 0.036
MCV 0** – P = 0.067 – P = 0.079
Previous alcohol-related seizure P = 0.082 – P = 0.068 –
Psychiatric comorbidity – – – P = 0.066
Type of discharge – – P = 0.069 –
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A higher educational level and being employed (as soci-
odemographic baseline variables) and less use of withdrawal 
medication, fewer previous hospitalizations and lower breath 
alcohol levels at admission (as clinical baseline variables) 
were significantly associated with better treatment outcome 
(Table 1). Even though no single baseline blood biomarker 
at admission was significantly associated with one outcome 
variable, the AST:ALT ratio significantly correlated with 
daily alcohol consumption at the 6-month follow-up. The 
combined threshold criterion of an AST:ALT > 1.00 and 
MCV > 90.0 fl was significantly associated with outcome, 
i.e. significantly more participants who did not fulfil the 
combination threshold criterion (low-risk patients) achieved 
current abstinence after 6 months than participants who 
fulfilled it (high-risk patients). High-risk patients achieved 
continuous abstinence for a significantly shorter period of 
time than low-risk patients and had a significantly higher 
mean daily alcohol consumption (Table 1). Moreover, the 
combination criterion was significantly associated with more 
outcome variables (3 out of 4) than any other biological 
and non-biological factors (Table 2). Finally, we performed 
a regression analysis to estimate effect sizes or odd ratios 
and to adjust for confounding within the tested variables. 
Regression analysis highlighted that the combination cri-
terion significantly predicted the three associated outcome 
variables. Moreover, all regression models that were based 
on the significant baseline variables from Table 1 provided 
significant models to predict part of the respective outcome 
variance.
In our study, 44.4% of the participants reported being 
continuously abstinent 6 months after inpatient treatment. 
This finding is consistent with previous studies reporting a 
Table 3  Logistic regression 
of the relationship between 
identified baseline variables on 
current abstinence
Logistic regression model of the relationship between identified baseline and current abstinence. Indepen-
dently significant associations (P < 0.05) are written in bold. Model statistics: χ2 = 22.723, df = 6, P < 0.001, 
Nagelkerke’s R square = 0.262
Df degrees of freedom, Wald χ2 value, Sig. = two-tailed P value
a Educational level vs. “secondary school to end of year 9”
b Not fulfilled vs. fulfilled
Predictors for current abstinence (logistic 
regression)
Wald df Sig Exp(B) 95% C.I. for 
EXP(B)
Lower Upper
Breath alcohol level 0.836 1 0.361 0.720 0.355 1.457
Education 11.021 3 0.012
Secondary school to end of year  10a 3.901 1 0.048 3.892 1.010 14.992
Secondary school to end of year 12/13a 0.227 1 0.634 0.728 0.196 2.696
University/collegea 6.362 1 0.012 5.665 1.472 21.801
AST:ALT > 1.00 + MCV > 90.0 flb 6.154 1 0.013 3.520 1.302 9.513
Dose of oxazepam needed 0.466 1 0.495 0.998 0.992 1.004
Table 4  Linear regression 
between identified baseline 
variables and daily alcohol 
consumption and continuous 
abstinence
(A) Linear regression model of the relationship between identified baseline variables on daily alcohol con-
sumption. Independently significant associations (P < 0.05) are written in bold. Model statistics: F = 6.092, 
P < 0.001, R square = 0.209. (B) Linear regression of the relationship between identified baseline variables 




(A) Predictors for daily alcohol consumption (linear regression)
Breath alcohol level 0.192 2.040 0.044
Education − 0.160 − 1.894 0.061
AST:ALT ratio − 0.108 − 1.108 0.270
AST:ALT > 1.00 + MCV > 90.0 fl—fullfilled 0.347 3.534 0.001
Dose of oxazepam needed 0.138 1.461 0.147
(B) Predictors for days of continuous abstinence (linear regression)
AST:ALT > 1.00 + MCV > 90.0 fl—fullfilled − 0.190 − 2.177 0.031
Previous inpatient treatment − 0.219 − 2.525 0.013
Employment status—Yes 0.048 0.548 0.584
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relapse rate of approximately 60% after alcohol treatment 
[11, 27]. Also in line with previous studies was our finding 
that the number of previous detoxifications [39] and sociode-
mographic factors such as employment status and a higher 
level of education [38] were associated with better treatment 
outcomes. However, a direct comparison with other studies 
is not possible, due to several differences between studies 
(e.g. treatment setting, study design and follow-up period).
In the current study, individual blood biomarkers were 
not significantly associated with the outcome variables and 
only the baseline AST:ALT ratio significantly correlated 
with daily alcohol consumption at the 6-month follow-up. 
However, we identified the combined threshold criterion of 
an AST:ALT ratio > 1.00 and MCV > 90.0 fl as a potentially 
powerful tool to identify patients with a lower and higher 
risk for relapse after withdrawal treatment. We did not use 
the threshold criterion from Kawachi et al. [17] as a screen-
ing tool to identify patients with AD, but as a potential pre-
dictor for future outcomes in patients with AD. It should 
be noted that at admission all participants met the criteria 
for AD according to ICD-10, but less than half of them met 
the threshold cut-offs of Kawachi et al. that were originally 
applied to identify AD patients. Remarkably, the combined 
threshold criterion was significantly associated with 3 out of 
4 outcome variables and thus outperformed all other base-
line variables (Table 2). High-risk patients reported current 
alcohol consumption significantly more often at the 6-month 
follow-up, were continuously abstinent for significantly 
shorter periods and consumed significantly more alcohol 
per day compared with low-risk patients. Only continuous 
abstinence as an outcome variable (which was lower in high-
risk patients) did not reach the level of significance, which 
might be due to the low sample size (Table 1). Remark-
ably, also when we adjusted for potentially confounding 
effects of other candidate baseline variables by performing 
regression analysis, the combination threshold criterion of 
AST:ALT > 1.00 and MCV > 90.0 fl significantly predicted 
parts of the outcome variables.
To our knowledge, only a few studies have investigated 
in cohorts of patients with AUD whether baseline values 
of routine blood biomarkers are associated with AUD-rel-
evant outcome variables. Maenhout et al. [23] suggested 
that ALT and GGT were predictors for drunk-driving 
recidivism. Florez and colleagues used all indirect alco-
hol blood biomarkers (GGT, AST, ALT, AST:ALT ratio 
and MCV) that were applied in this study and revealed 
the potential of indirect alcohol markers [14]. However, 
they had a more general interpretation of good clinical 
response without detailed distinction of abstinence or daily 
alcohol consumption. Moreover, there were two assess-
ment time points: one at baseline before treatment and 
one after 6 months when the active intervention period 
was completed. Biomarkers at both time points were tested 
for their potential to predict the outcome after 18 months. 
For 18 months’ prediction, 6 months biomarkers were 
more important than baseline parameters [14]. Moreover, 
GGT was previously identified as a potential predictor 
and was part of algorithms that applied GGT among other 
factors to calculate abstinence from drinking [1, 15, 16]. 
Our analyses confirmed that biological variables, already 
determined at admission, might help to predict long-term 
abstinence and the risk of relapse. However, in our study, 
only the combination of blood biomarkers was signifi-
cantly associated with 6-months outcome variables.
A multitude of clinical decision limits can be applied to 
the De Ritis or AST:ALT ratio [7]. An AST:ALT ratio > 1.0 
might be an indicator of liver fibrosis/cirrhosis or a resolving 
alcoholic hepatitis although > 1.0 but < 1.5 could be also a 
healthy condition in women, whereas an AST:ALT ratio ≥ 2 
in adults is associated with worse prognosis of relevant liver 
damage [7]. The MCV represents a measure for the average 
size of erythrocytes and is an established biomarker for alco-
hol abuse and AD [9]. Nevertheless, elevated MCV levels 
being above the established upper limit of 90 fl might also 
be affected by other factors, such as e.g. smoking behaviour, 
poor nutrition and aging [33]. Despite its low sensitivity 
as a single biological screening marker to detect alcohol-
ism, MCV can enhance sensitivity to detect alcoholism 
when combined with other alcohol-specific markers such 
as e.g. GGT [30]. A previous large US population-based 
study found that these markers identify very heavy alcohol 
drinking but fail to identify potentially harmful lower levels 
of alcohol intake [21].
Despite a range of uncertainty, indirect alcohol blood bio-
markers and their combinations could reflect the degree of 
previous alcohol consumption that also reflects the severity 
of AD [35]. Moreover, it is very likely that the severity of 
AD is also linked to the risk of relapse after alcohol with-
drawal treatment [6]. Therefore, blood biomarkers might 
help to identify patients with more severe AD and a higher 
risk of relapse.
This study has several limitations. We did not assess 
motivation or self-efficacy in participants, although both 
are associated with treatment outcome [10, 22, 28]. Moreo-
ver, the follow-up data are based on self-reports and did 
not include collateral reports [41] or biomarkers to validate 
self-reported drinking behaviour. However, previous studies 
revealed that self-reported alcohol consumption correlates 
with blood biomarkers [4, 34]. Furthermore, the sample size 
was relatively small and is based on only one centre with a 
limited follow-up period although 6 months’ outcome is a 
good predictor for 5-year abstinence [40]. Therefore, our 
findings need to be confirmed in a multicentre study with 
a larger study population. In this study, we did not assess 
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biomarkers like carbohydrate-deficient transferrin (CDT) 
or direct-ethanol metabolites such as phosphatidylethanol 
(PEth), ethyl glucuronide (EtG) or ethylsulfate (EtS) [42]. 
On the other hand, the use of those specific molecules also 
entails shortcomings that need to be considered. In contrast 
to AST, ALT, GGT and MCV that are standard parameters 
in clinical laboratories, these tests are more expensive and 
only available in specialized centres [3]. Moreover, the direct 
biomarkers might be more powerful to detect relapse and 
monitor abstinence but less powerful to monitor clinically 
relevant chronic cellular impairments in blood samples that 
could also reflect the somatic severity of AD.
Conclusion
In summary, this study highlights that, besides sociode-
mographic and clinical factors, routinely assessed indirect 
alcohol biomarkers might be useful in the future prediction 
of long-term outcome in alcohol withdrawal treatment and 
the identification of patients who have a more severe degree 
of AD and/or higher risk of relapse. Previously, Neumann 
and Spies [31] suggested using defined outcome variables to 
determine the value of single or combined blood biomarkers 
for future clinical decision-making algorithms with regard 
to treatment as usual or intensified treatment. Indirect alco-
hol biomarkers might support future treatment algorithms in 
daily routine care. Our study might help to pave the way for 
personalized medicine in AUD treatment with an evidence-
based risk stratification and personalized risk prediction 
that comprises both biological and non-biological factors to 
identify high-risk patients who might need more intensified 
treatment and/or relapse prevention.
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